Epicrispr Biotechnologies

Epicrispr Biotechnologies company information, Employees & Contact Information

Updated June 2026

Quick answer

Epicrispr Biotechnologies is a Biotechnology Research company and founded in 2018. It has approximately 38 employees on record. Contact data was last refreshed in June 2026. Find Epicrispr Biotechnologies's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Epicrispr Biotechnologies email format Epicrispr Biotechnologies management contacts

Related company profiles:

Epicrispr Biotechnologies is a biotechnology company developing ultracompact therapies to modulate gene expression in vivo using the smallest known Cas protein, CasMINI.

Company Details

Employees
38
Founded
2018
Address
7000 Shoreline Ct,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
https://epicrispr.com/
HQ
South San Francisco, CA
Competitors
Biolinq, Prellis Biologics, Arbor Biotechnologies, MapLight Therapeutics, Inc., Dispatch Bio, Proscia, Orca Bio, Olaris, Inc, Matterworks, AIRNA.
Looking for a particular Epicrispr Biotechnologies employee's phone or email?

Epicrispr Biotechnologies Questions

News

Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy - Business Wire

Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy Business Wire

Press Release Service: Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual Meeting - CRISPR Medicine News

Press Release Service: Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual Meeting CRISPR Medicine News

Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients - Genetic Engineering and Biotechnology News

Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients Genetic Engineering and Biotechnology News

Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD - Business Wire

Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD Business Wire

Epicrispr banks $68M to test epigenetic editing on rare muscle disease - BioPharma Dive

Epicrispr banks $68M to test epigenetic editing on rare muscle disease BioPharma Dive

Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD - Business Wire

Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD Business Wire

Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT - GlobeNewswire

Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT GlobeNewswire

Epicrispr exploring AI muscle-imaging biomarker in muscular dystrophy study - FirstWord Pharma

Epicrispr exploring AI muscle-imaging biomarker in muscular dystrophy study FirstWord Pharma

Next-generation CRISPR company raises $68 million, zeroes in on first clinical trial - The Business Journals

Next-generation CRISPR company raises $68 million, zeroes in on first clinical trial The Business Journals

Epicrispr Biotechnologies - The Pharma Letter

Epicrispr Biotechnologies The Pharma Letter

Epicrispr Biotechnologies: $68 Million (Series B) Raised For Developing Curative Therapies - Pulse 2.0

Epicrispr Biotechnologies: $68 Million (Series B) Raised For Developing Curative Therapies Pulse 2.0

EpiCRISPR targeted methylation of Arx gene initiates transient switch of mouse pancreatic alpha to insulin-producing cells - Frontiers

EpiCRISPR targeted methylation of Arx gene initiates transient switch of mouse pancreatic alpha to insulin-producing cells Frontiers

Companies like Epicrispr Biotechnologies

Orca Bio logo - Similar company to Epicrispr Biotechnologies

Orca Bio

215
Proscia logo - Similar company to Epicrispr Biotechnologies

Proscia

126
Biolinq logo - Similar company to Epicrispr Biotechnologies

Biolinq

100
Olaris, Inc logo - Similar company to Epicrispr Biotechnologies

Olaris, Inc

14
AIRNA logo - Similar company to Epicrispr Biotechnologies

Airna

71
Prellis Biologics logo - Similar company to Epicrispr Biotechnologies

Prellis Biologics

50
Arbor Biotechnologies logo - Similar company to Epicrispr Biotechnologies

Arbor Biotechnologies

114
Dispatch Bio logo - Similar company to Epicrispr Biotechnologies

Dispatch Bio

59
Matterworks logo - Similar company to Epicrispr Biotechnologies

Matterworks

41
MapLight Therapeutics, Inc. logo - Similar company to Epicrispr Biotechnologies

Maplight Therapeutic...

99

Top Epicrispr Biotechnologies Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant